Prognostic implications of a molecular classifier derived from whole‐exome sequencing in nasopharyngeal carcinoma. (5th April 2019)

• Record Type: Journal Article
• Authors: Wang, Hai‐Yun; Li, Fugen; Liu, Na; Liu, Xiao‐Yun; Yang, Xin‐Hua; Guo, Yun‐Miao; Bei, Jin‐Xin; Zeng, Yi‐Xin; Shao, Jian‐Yong
• Is Part Of: Cancer medicine. Volume 8:Number 6(2019:Jun.)
• Page Start: 2705
• Page End: 2716
• Publication Date: 2019-04-05
• Subjects: copy number variants -- indels -- molecular classifier -- nasopharyngeal carcinoma -- single‐nucleotide variants; 616.994005
• DOI: 10.1002/cam4.2146
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: The aim of this study was to use whole‐exome sequencing to derive a molecular classifier for nasopharyngeal carcinoma (NPC) and evaluate its clinical performance. We performed whole‐exome sequencing on 82 primary NPC tumors from Sun Yat‐sen University Cancer Center (Guangzhou cohort) to obtain somatic single‐nucleotide variants, indels, and copy number variants. A novel molecular classifier was then developed and validated in another NPC cohort (Hong Kong cohort, n = 99). Survival analysis was estimated by the Kaplan‐Meier method and compared using the log‐rank test. Cox proportional hazards model was adopted for univariate and multivariate analyses. We identified three prominent NPC genetic subtypes: RAS/PI3K/AKT (based on RAS, AKT1, and PIK3CA mutations), cell‐cycle (based on CDKN2A / CDKN2B deletions, and CDKN1B and CCND1 amplifications), and unclassified (based on dominant mutations in epigenetic regulators, such as KMT2C / 2D, or the Notch signaling pathway, such as NOTCH1 / 2 ). These subtypes differed in survival analysis, with good, intermediate, and poor progression‐free survival in the unclassified, cell‐cycle, and RAS/PI3K/AKT subgroups, respectively, among the Guangzhou, Hong Kong, and combined cohorts (n = 82, P = 0.0342; n = 99, P = 0.0372; and n = 181, P = 0.0023; log‐rank test). We have uncovered genetic subtypes of NPC with distinct mutations and/or copy number changes, reflecting discrete paths of NPC tumorigenesis and providing a roadmap for developing new prognostic biomarkers and targeted therapies. Abstract : We proposed three prominent NPC genetic subtypes: RAS/PI3K/AKT, cell‐cycle, and unclassified using the whole‐exome sequencing. Survival analysis indicated that there were statistically significant among patients with three subgroups. This result reflects the genetic alterations of NPC with distinct mutations and/or copy number changes and provides a roadmap for developing new prognostic biomarkers and targeted therapies.